1
TITLE: Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir plus dasabuvir +/- ribavirin in the TOPAZ-I and TOPAZ-II trials
AUTHORS: Fred Poordad; Rui Sarmento E Castro; Armen Asatryan; Humberto Aguilar; Patrice Cacoub; Douglas Dieterich; Rui Marinho; Armando Carvalho; Asma Siddique; Yiran R Hu; Mariem Charafeddine; Mark Bondin; Nader Khan; Daniel Cohen; Franco Felizarta;
PUBLISHED: 2019, SOURCE: International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL) in JOURNAL OF HEPATOLOGY, VOLUME: 70
INDEXED IN: WOS
2
TITLE: Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I  Full Text
AUTHORS: Kosh Agarwal; Emily O Dumas; Giovanni B Gaeta; Sam Lee; Adrian Streinu Cercel; Eckart Schott; Raul J Andrade; Alma M Perez; Jacob George; Igor G Bakulin; Rui T Marinho; Resat Ozaras; Mariem Charafeddine; Li Liu; Tami Pilot Matias; Kevin Howieson; Melannie Co; Daniel E Cohen; Fabien Zoulim;
PUBLISHED: 2016, SOURCE: 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) in HEPATOLOGY, VOLUME: 64
INDEXED IN: WOS